Anjaneyulu Alapati, MD
Neurology · Huntsville, ALNPI 1992791297
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,587 of the $133,291 with a category attached, or 62.7%. 60 manufacturers reported payments, led by SK Life Science, Inc. at 33.6% of the total. Reporting peaked in 2023 at $29,720 and has fallen 62.7% since, to $11,097 in 2025. Among neurology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,816 payments — averaging $73.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$45K
- UCB, Inc.$39K
- Eisai Inc.$12K
- AbbVie$5K
- Novartis$5K
- Catalyst Pharmaceuticals, Inc.$4K
- plus $24K from 54 others
What the payments were for
- Consulting fees$8,3106%
- Speaking & faculty fees$83,58763%
- Travel & lodging$5,8084%
- Food & beverage$32,50024%
- Education$2270%
- Gifts$2,8592%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,291 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $303,249 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $215,371 |
| Kesimpta PenOfatumumab | 15 | $172,570 |
| EpidiolexCannabidiol (Cbd) | 35 | $164,815 |
| BriviactBrivaracetam | 156 | $150,519 |
| FinteplaFenfluramine Hcl | 12 | $135,654 |
| Plegridy PenPeginterferon Beta-1a | 14 | $132,820 |
| FycompaPerampanel | 85 | $98,362 |
| CopaxoneGlatiramer Acetate | 13 | $76,073 |
| XcopriCenobamate | 49 | $54,580 |
| Aimovig AutoinjectorErenumab-Aooe | 33 | $41,613 |
| Levetiracetam | 1,119 | $25,869 |
| Lacosamide | 290 | $24,475 |
| Nurtec OdtRimegepant Sulfate | 14 | $14,619 |
| Gabapentin | 1,166 | $14,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $884 | $303,24937 claims |
| UCB, Inc.Briviact, Fintepla, Nayzilam | $38,591 | $294,796181 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $105 | $215,37117 claims |
| Eisai Inc.Fycompa | $11,588 | $98,36285 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $635 | $76,07313 claims |
| SK Life Science, Inc.Xcopri | $44,773 | $54,58049 claims |
| PfizerNurtec Odt | $443 | $14,61914 claims |
| AbbVieUbrelvy | $4,886 | $12,61014 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $113 | $3,90444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 neurology providers in Alabama.
Other neurology in Huntsville
- Harry McDarisHuntsville$307K
- Belinda Savage-EdwardsHuntsville$296K
- Bhageeradh MulpurHuntsville$74K
- David GreerHuntsville$67K
- Scott HitchcockHuntsville$41K
- David WhiteHuntsville$40K
- Amit AroraHuntsville$22K
- Jitesh KarHuntsville$18K
- Diane CounceBirmingham$895K
- Daniel DeesMobile$799K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.